Multiple Endocrine Neoplasia clinical trials
The registry lists 18 studies for Multiple Endocrine Neoplasia across 6 countries. 5 are recruiting or about to start. 9 of them are mainly about Multiple Endocrine Neoplasia (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28.
Get an email when these change. Save the Multiple Endocrine Neoplasia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Centre Hospitalier Universitaire Dijon (2) · Federico II University (1) · Sanford Health (1) · Charles Mel Wilcox, MD (1) · Hospital Italiano de Buenos Aires (1) · Pamela L. Kunz (1)
What is being tested here
Drugs under test in Multiple Endocrine Neoplasia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Leflunomide | 1 | 0 | 1 |
| Gallium Ga 68 dotatate | 0 | 0 | 1 |
| Vandetanib | 0 | 0 | 1 |
| Lansoprazole | 0 | 0 | 1 |
| Pertuzumab | 0 | 0 | 1 |
Who these studies take
Of the 5 Multiple Endocrine Neoplasia studies recruiting now, 4 (80%) set no upper age limit and 1 (20%) stop at 75 or younger. 4 (80%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (80%) | 4 (80%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 4 (80%) | 4 (80%) |
Across all 18 studies, recruiting or not: 11% stop at 75 or younger and 6% at 65; 61% take children; 0% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 18 of 18. search them.
- Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordRecruitingNCT017931681 country
- Institutional Registry of Rare DiseasesRecruitingNCT065737231 country
- Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine TumorRecruitingNCT06540937Phase 21 country
- Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 PatientsRecruitingNCT030482661 country
- Study and Follow-up of Multiple Endocrine Neoplasia Type 1RecruitingNCT033485011 country
- Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2Active, not recruitingNCT030482791 country
- The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT040284791 country
- A Retrospective Study for Multiple Endocrine NeoplasiaStatus unknownNCT058125731 country
- Studies of Inherited Diseases of MetabolismCompletedNCT000013451 country
- Studies of Elevated Parathyroid ActivityCompletedNCT00001277Phase 21 country
- Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedNCT00514046Phase 1/21 country
- Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) SyndromesCompletedNCT005014491 country
- Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)Status unknownNCT030539991 country
- Type 1 Multiple Endocrine Neoplasia Cohort StudyStatus unknownNCT032621291 country
- Cinacalcet to Treat Familial Primary HyperparathyroidismCompletedNCT00325104Phase 31 country
- A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsTerminatedNCT00947167Phase 21 country
- Treatment of Zollinger-Ellison Syndrome With PrevacidCompletedNCT00204373Phase 4
- High Dose Somatostatin Analogues in Neuroendocrine TumorsCompletedNCT00990535Phase 21 country